The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2021 | CAR-T in DLBCL: 4-year follow-up data from ZUMA-1
Anna Sureda, MD, PhD, Catalan Institute of Oncology, Barcelona, Spain, discusses the four-year follow-up data from the pivotal ZUMA-1 trial of axicabtagene ciloleucel (axi-cel) in adult patients with refractory diffuse large B-cell lymphoma (DLBCL). The four-year overall survival rate among patients after a single infusion of axi-cel was 44%. These are very encouraging results considering the heavily pre-treated patient population included in the pivotal clinical trial. Furthermore, there were no additional toxicity signs reported in this long-term follow-up analysis. This interview took place during the 3rd European CAR T-cell Meeting.
Disclosures
Honoraria from Gilead Kite, Novartis and Celgene/BMS
